Format: Recorded Webinar
CE Credits available until: May 31, 2021
Target Audience
Nurse practitioners, nurses and oncology social workers involved in the care of patients with myeloproliferative neoplasms (MPNs).
Course content level: Intermediate and Advanced
Description
This webinar will provide a basic overview of myeloproliferative neoplasms (MPNs), focusing on strategies for diagnosis and patient management. Risk assessment, treatment options, the role of various members of the healthcare team in addressing treatment goals, guidance for patients and caregivers in treatment decision making, as well as resources for patients, caregivers and healthcare providers will be discussed.
Learning Objectives
At the conclusion of this program, participants will be able to:
- Describe the types of myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia
- Identify tests used to diagnose disease and monitor treatment
- Explain the overarching goals of treatment for the various types of myeloproliferative neoplasms
- Explain approved and emerging treatment options for myeloproliferative neoplasms including, stem cell transplantation, and the role of clinical trials
- Describe strategies to manage treatment side effects as well as potential long-term and late effects of treatments
- Identify resources for patients, caregivers and healthcare providers
Faculty
Michael J. Mauro, MD
Professor of Medicine
Leader, Myeloproliferative Neoplasms Program
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Charlene Kabel, PharmD, BCOP
Clinical Pharmacy Specialist
Leukemia Service, Department of Pharmacy
Memorial Sloan Kettering Cancer Center
New York, NY
Carolanne Carini, BSN, RN, BMTCN
Office Practice Nurse, Medical Oncology
Memorial Sloan Kettering Cancer Center
New York, NY
Continuing Education
This activity is approved for 1.25 contact hour(s) of continuing education (which includes 1.25 hours of pharmacology) by the American Association of Nurse Practitioners. Activity ID ID 20044256. This activity was planned in accordance with AANP Accreditation Standards and Policies.
Approval for nurses has been obtained by the National Office of The Leukemia & Lymphoma Society under Provider Number CEP 5832 to award 1.25 continuing education contact hours through the California Board of Registered Nursing.
The Leukemia & Lymphoma Society (LLS) Provider Number 1105, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. LLS maintains responsibility for this course. ACE provider approval period: 12/10/2020-12/10/2023. Social workers completing this course receive 1.25 continuing education credits.
The Leukemia & Lymphoma Society (LLS) is recognized by the New York State Education Departments State Board for Social Work as an approved provider of continuing education for licensed social workers #0117. LLS maintains responsibility for the program. Social workers will receive 1.25 clinical CE contact hours for this activity.
Participants must attend the free webinar in its entirety, pass the post-test with 70% or higher, and submit the online evaluation form to earn credit. Once submitted, the certificate will be automatically generated as a PDF online.
Providers
This program is provided by The Leukemia & Lymphoma Society.
Participants gain access to the webinar via the registration button above.
To view system requirements please visit https://llsce.org/system-requirements.
For questions, concerns, or for assistance for people with disabilities or grievances, please contact us at infocenter@LLS.org.
< Back to Continuing Education